These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23375565)

  • 21. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.
    Fukumoto H; Tokuda T; Kasai T; Ishigami N; Hidaka H; Kondo M; Allsop D; Nakagawa M
    FASEB J; 2010 Aug; 24(8):2716-26. PubMed ID: 20339023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surface Assay for Specific Detection of Soluble Amyloid Oligomers Utilizing Pronucleon Peptides Instead of Antibodies.
    Matveeva EG; Moll JR; Khan MM; Thompson RB; Cliff RO
    ACS Chem Neurosci; 2017 Jun; 8(6):1213-1221. PubMed ID: 28290668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissociation of β-amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates β-amyloid-42 assembly.
    Takamura A; Kawarabayashi T; Yokoseki T; Shibata M; Morishima-Kawashima M; Saito Y; Murayama S; Ihara Y; Abe K; Shoji M; Michikawa M; Matsubara E
    J Neurosci Res; 2011 Jun; 89(6):815-21. PubMed ID: 21394760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence that a synthetic amyloid-ß oligomer-binding peptide (ABP) targets amyloid-ß deposits in transgenic mouse brain and human Alzheimer's disease brain.
    Chakravarthy B; Ito S; Atkinson T; Gaudet C; Ménard M; Brown L; Whitfield J
    Biochem Biophys Res Commun; 2014 Mar; 445(3):656-60. PubMed ID: 24569075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease.
    Wang SW; Liu DQ; Zhang LX; Ji M; Zhang YX; Dong QX; Liu SY; Xie XX; Liu RT
    Alzheimers Res Ther; 2017 Jun; 9(1):41. PubMed ID: 28592267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease.
    Gao CM; Yam AY; Wang X; Magdangal E; Salisbury C; Peretz D; Zuckermann RN; Connolly MD; Hansson O; Minthon L; Zetterberg H; Blennow K; Fedynyshyn JP; Allauzen S
    PLoS One; 2010 Dec; 5(12):e15725. PubMed ID: 21209907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
    Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
    Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
    Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
    Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
    J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease.
    Wang-Dietrich L; Funke SA; Kühbach K; Wang K; Besmehn A; Willbold S; Cinar Y; Bannach O; Birkmann E; Willbold D
    J Alzheimers Dis; 2013; 34(4):985-94. PubMed ID: 23313925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity.
    Bao F; Wicklund L; Lacor PN; Klein WL; Nordberg A; Marutle A
    Neurobiol Aging; 2012 Apr; 33(4):825.e1-13. PubMed ID: 21683475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
    Hey JA; Kocis P; Hort J; Abushakra S; Power A; Vyhnálek M; Yu JY; Tolar M
    CNS Drugs; 2018 Sep; 32(9):849-861. PubMed ID: 30076539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients.
    Sancesario GM; Cencioni MT; Esposito Z; Borsellino G; Nuccetelli M; Martorana A; Battistini L; Sorge R; Spalletta G; Ferrazzoli D; Bernardi G; Bernardini S; Sancesario G
    J Alzheimers Dis; 2012; 31(4):865-78. PubMed ID: 22717612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of Aβ oligomer levels in matched cerebrospinal fluid and serum samples.
    Kasai T; Tokuda T; Taylor M; Kondo M; Mann DM; Foulds PG; Nakagawa M; Allsop D
    Neurosci Lett; 2013 Sep; 551():17-22. PubMed ID: 23811027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma.
    Michno W; Blennow K; Zetterberg H; Brinkmalm G
    J Neurochem; 2021 Oct; 159(2):234-257. PubMed ID: 34245565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
    J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.